Zur Kurzanzeige

dc.creatorBegas, E.en
dc.creatorKouvaras, E.en
dc.creatorTsakalof, A.en
dc.creatorPapakosta, S.en
dc.creatorAsprodini, E. K.en
dc.date.accessioned2015-11-23T10:23:42Z
dc.date.available2015-11-23T10:23:42Z
dc.date.issued2007
dc.identifier10.1002/bmc.736
dc.identifier.issn0269-3879
dc.identifier.urihttp://hdl.handle.net/11615/26220
dc.description.abstractA RP-HPLC method was developed for the assessment of caffeine and its metabolites in urine and was used for the evaluation of the CYP1A2, CYP2A6, xanthine oxidase (XO) and N-acetyl-transferase-2 (NAT-2) in vivo activities in 44 Greek volunteers (21 men, 23 women). Spot urine samples were analyzed 6 h after 200 mg caffeine consumption, following a 30 h methylxantine-free diet. The major urinary caffeine metabolites are 1-methyluric acid (1U), 5-acetylamino-6-formylamino-3-methyluracil (AFMU), 1-methylxanthine (1X), 1,7-dimethyluric acid (17U) and 1,7-dimethylxanthine (17X). CYP1A2, CYP2A6, XO and NAT-2 activities were estimated from the metabolic ratios (AFMU + 1U + 1X)/17U, 17U/17X, 1U/(1X + 1U) and AFMU/(AFMU + 1U + 1X), respectively. Metabolites and internal standard were extracted with chlorofonn/isopropanol (85:15, v/v) and separated on a C-18 column by an isocratic HPLC system using a two-step elution with manual switch from solvent A (0.1% acetic acid-methanol-acetonitrile, 92:4:5 v/v) to solvent B (0.1% acetic acid-methanol, 60:40, v/v), and detected at 280 nm. The method exhibited adequate metabolite separation (resolution factors > 1.48), accuracy (94.1-106.3%) and intraday and interclay precision < 8.02 and < 8.78%, respectively (n = 6). Smoking affected only CYP1A2, whereas gender had no effect in any enzyme activity. NAT-2 exhibited bimodal distribution, 63.6% of volunteers being slow acetylators. The developed RP-HPLC method was fully validated and successfully applied for the evaluation of CYP1A2, CYP2A6, XO and NAT-2 activities. Copyright (c) 2007 John Wiley & Sons, Ltd.en
dc.sourceBiomedical Chromatographyen
dc.source.uri<Go to ISI>://WOS:000244218800010
dc.subjectCYP1A2en
dc.subjectCYP2A6en
dc.subjectXOen
dc.subjectNAT-2en
dc.subjectHPLCen
dc.subjectcaffeineen
dc.subjectPERFORMANCE LIQUID-CHROMATOGRAPHYen
dc.subjectHUMAN-LIVER-MICROSOMESen
dc.subjectBLADDER-CANCER-RISKen
dc.subjectN-ACETYLTRANSFERASEen
dc.subjectEXTRACTIONLESS METHODen
dc.subjectMASS-SPECTROMETRYen
dc.subjectENZYME-ACTIVITYen
dc.subjectURINEen
dc.subjectPHENOTYPEen
dc.subjectOXIDATIONen
dc.subjectBiochemical Research Methodsen
dc.subjectBiochemistry & Molecular Biologyen
dc.subjectChemistry, Analyticalen
dc.subjectPharmacology & Pharmacyen
dc.titleIn vivo evaluation of CYP1A2 CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratiosen
dc.typejournalArticleen


Dateien zu dieser Ressource

DateienGrößeFormatAnzeige

Zu diesem Dokument gibt es keine Dateien.

Das Dokument erscheint in:

Zur Kurzanzeige